VOGIVOC-0.3
March 31, 2026
VOGIVOC-GM2/0.3
₹1,290.00
Composition:
Vogli 0.3 mg, Glimepiride 2 mg, Metformin 500 mg
Packaging Detail:
10 x 10
Description
A triple combination tablet for type 2 diabetes containing Voglibose (alpha-glucosidase inhibitor), Glimepiride (sulfonylurea), and sustained-release Metformin (insulin sensitizer). It provides comprehensive glycemic control through three complementary mechanisms.
Indications:
Indications:
-
Type 2 diabetes mellitus inadequately controlled on dual therapy.
-
As an adjunct to diet and exercise for intensive glycemic management.
Side Effects
Side Effects
-
Hypoglycemia (significant risk due to Glimepiride).
-
Flatulence, abdominal distension, and diarrhea (due to Voglibose).
-
Nausea, vomiting, and metallic taste (due to Metformin).
-
Weight gain (due to Glimepiride).
-
Rare risk of lactic acidosis.
Reviews 0
Related products
-
BECOMEL A TO Z
₹1,100.00 -
ASTORMEL-20
₹1,100.00 -
AZIMEL-250
₹787.50
Reviews
There are no reviews yet.